AstraZeneca Results Presentation Deck
Lynparza
The globally leading PARP inhibitor across four tumour types
$m
700
600
500
400
300
200
100
0
Q3
Product sales
31% growth to $1.7bn
Q4 Q1
2019
US Europe EROW EM
Q2
Q3 Q4
2020
Q1
Q2
2021
Q3
Growth in all regions
Approvals: 86 (OC), 84 (mBC), 70 (mCRPC)
●
US +26%
Ovarian and prostate see strong growth, with
breast also contributing. OlympiA inclusion in
NCCN guidelines benefited Q3
Europe +36%
Increasing HRD testing, strong share
performance and PROfound launch in
Germany
EROW +29%
Japan +22% - strong PAOLA-1 launch
EM +40%
China +28% with strong demand growth
supported by PAOLA-1 NRDL. Inventory
phasing driving quarterly volatility
Collaboration revenue¹
$3.1bn recorded, $4.6bn future potential
$m
1,000
900
800
700
600
500
400
300
200
100
0
J
Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3
2017
2018
2020
2021
Upfront payment Option payments Regulatory milestones Sales milestones
16 PARP = poly ADP-ribose polymerase; OC = ovarian cancer; mBC = metastatic breast cancer; mCRPC = metastatic castration resistant prostate cancer. 1. at actual exchange rates. Lynparza is being developed and commercialised in
collaboration with Merck & Co., Inc., Kenilworth, NJ, US, known as MSD outside the US and Canada.
2019View entire presentation